文献速递鼻科

组胺H4受体基因多态性:口服H1抗组胺药治疗过敏性鼻炎疗效的潜在预测因子

Histamine H4 receptor gene polymorphisms: a potential predictor of oral H1 antihistamine efficacy for allergic rhinitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2016-11-26

研究纳入142例过敏性鼻炎患者和160名健康对照,检测HRH4基因三个单核苷酸多态性,并评估口服H1抗组胺药疗效。结果发现rs77485247和rs77041280突变基因型患者治疗后特异性IgE、ECP及VAS评分更高,不良反应发生率和总有效率更低。

要点

  • rs77485247突变基因型(TA+AA)患者总有效率低于TT基因型,不良反应更少。
  • rs77041280突变基因型(AT+TT)患者总有效率低于AA基因型,不良反应更少。
  • rs74604924突变基因型与AA基因型间未发现差异。

核心结论

  • HRH4 rs77485247和rs77041280多态性可能与过敏性鼻炎风险及H1抗组胺药疗效相关。

研究设计与样本

  • 病例对照研究,纳入142例过敏性鼻炎患者为病例组,160名健康个体为对照组。
  • 采用直接测序检测HRH4基因单核苷酸多态性,酶联免疫吸附试验测定血清IgE、特异性IgE和ECP水平。
  • 采用视觉模拟量表评估临床疗效,并记录不良反应发生情况。

主要发现

  • rs77485247突变基因型(TA+AA)和A等位基因、rs74604924突变基因型(AT+TT)和T等位基因、rs77041280突变基因型(AT+TT)和T等位基因在病例组与对照组间分布频率有显著差异。
  • rs77485247突变基因型(TA+AA)患者较TT基因型患者治疗后特异性IgE、ECP水平和VAS评分更高,不良反应发生率和总有效率更低。
  • rs77041280突变基因型(AT+TT)患者较AA基因型患者治疗后特异性IgE、ECP水平和VAS评分更高,不良反应发生率和总有效率更低。
  • rs74604924突变基因型(AT+TT)与AA基因型患者之间未发现差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our study aimed to investigate the associations between Histamine H4 receptor (HRH4) gene polymorphisms (rs77485247, rs74604924, and rs77041280) and oral H1 antihistamine efficacy for the treatment of allergic rhinitis (AR) patients. METHODS: A total of 142 AR patients were selected as a case group and 160 healthy individuals were recruited as a control group. Single nucleotide polymorphisms (SNPs) in the HRH4 gene were detected using direct sequencing. Serum immunoglobulin E (IgE), specific IgE, and eosinophil cationic protein (ECP) levels were measured by enzyme-linked immunosorbent assay (ELISA). Clinical efficacy was evaluated by the visual analogue scale (VAS). The occurrence of adverse reaction was recorded. RESULTS: There were significant differences in the distribution frequencies of mutant genotype (TA + AA) and A allele of rs77485247, mutant genotype (AT + TT) and T allele of rs74604924, and mutant genotype (AT + TT) and T allele of rs77041280 between the case and control groups. AR patients with mutant genotype (TA + AA) of rs77485247 and AR patients with mutant genotype (AT + TT) of rs77041280 had higher specific IgE, ECP levels, and VAS scores after treatment and lower incidence of adverse reactions and total effective rate than those with TT genotype and those with AA genotype, respectively. However, for rs74604924, there were no differences was found between AR patients with mutant genotype (AT + TT) and those with AA genotype. CONCLUSION: Our findings provide evidence that HRH4 rs77485247 and rs77041280 polymorphisms may be associated with the risk of AR and the efficacy of H1 antihistamines for the treatment of AR patients.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Gu J, Mao XH, Yang XZ, et al. Histamine H4 receptor gene polymorphisms: a potential predictor of oral H1 antihistamine efficacy for allergic rhinitis. Int Forum Allergy Rhinol. 2016. PMID: 27888642. doi:10.1002/alr.21870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。